Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Single-cell transcriptome profiling of tumour tissue isolates allows the characterization of heterogeneous tumour cells along with neighbouring stromal and immune cells. Here we adopt this powerful approach to breast cancer and analyse 515 cells from 11 patients. Inferred copy number variations from the single-cell RNA-seq data separate carcinoma cells from non-cancer cells. At a single-cell resolution, carcinoma cells display common signatures within the tumour as well as intratumoral heterogeneity regarding breast cancer subtype and crucial cancer-related pathways. Most of the non-cancer cells are immune cells, with three distinct clusters of T lymphocytes, B lymphocytes and macrophages. T lymphocytes and macrophages both display immunosuppressive characteristics: T cells with a regulatory or an exhausted phenotype and macrophages with an M2 phenotype. These results illustrate that the breast cancer transcriptome has a wide range of intratumoral heterogeneity, which is shaped by the tumour cells and immune cells in the surrounding microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Limited T-cell recruitment and function in the TME correlates with poor prognosis in BC (21,22).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · cited 1×
“4.0b (default parameters) 55 , and relative gene expression was quantified as transcript per million (TPM) using RSEM v1.”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440 · cited 1×
“To assess gene expression signatures and pathway activation, a non-parametric and unsupervised software algorithm called GSVA software in the R package 58 with the RNA-seq mode was used.”
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778 · cited 1×
“To further delineate the identity of carcinoma and non-carcinoma cells, we analysed the expression of tumour-associated stromal or immune gene sets proposed in the tumour purity estimation, ESTIMATE 26 .”
Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets.
Macosko, E. Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A. R., Kamitaki, N., Martersteck, E. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.002 · Cited by 7,110
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097 · cited 1×
“1) 20–22 .”
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · cited 8×
“Whole-exome sequencing revealed the genomic landscape of these samples regarding somatic mutations (Supplementary Data 1) and copy number variations (CNVs; Supplementary Data 2).”
InfluentialSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 2×
“T lymphocytes in four patient tumours manifested distinct patterns for naive, costimulatory, regulatory, exhaustion and cytotoxicity expression signatures 39–41 .”
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422 · cited 2×
“Three immune cell subgroups were identified by non-negative factorization clustering 60 from 175 non-tumour cells using 412 genes annotated in 11 non-overlapping immune cell types 37 (Supplementary Table 3).”
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · cited 2×
“The role of the immune system in tumour progression has been extensively studied, and the results of these studies have provided the basis for successful immunotherapy in multiple cancer types 12,42 .”
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · cited 5×
“Previous reports suggest that TAMs may show an immunosuppressive M2 signature, which promotes tumorigenesis by suppressing immune surveillance and inducing angiogenesis, rather than the activating M1-type signature 45 .”
InfluentialSalgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709 · cited 3×
“The role of the immune system in tumour progression has been extensively studied, and the results of these studies have provided the basis for successful immunotherapy in multiple cancer types 12,42 .”
Martinez, F. O., Gordon, S., Locati, M., & Mantovani, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7303 · Cited by 2,125
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056 · cited 1×
“To remove cells with low-quality sequencing values, four filtering criteria were applied: (1) number of total reads; (2) mapping rate; (3) number of detected genes; and (4) portion of intergenic region.”
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,687 · cited 1×
“Micro-environmental gene expression signatures may themselves present prognostic values independent of the intrinsic tumour subtype 8–10 .”
A flexible R package for nonnegative matrix factorization
Gaujoux, R., & Seoighe, C. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-367 · Cited by 1,547
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
Genome-wide analysis of DNA copy-number changes using cDNA microarrays
Pollack, J. R., Perou, C. M., Alizadeh, A. A., Eisen, M. B., Pergamenschikov, A., Williams, C. F., Jeffrey, S. S., Botstein, D., & Brown, P. O. (1999) · Nature Genetics · doi:10.1038/12640 · Cited by 1,423 · cited 1×
“Here gene expression profiles were aligned along the chromosomes as moving averages 24,25 .”
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S., Javinal, V., Chiu, H., Irving, B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,194
Sequence analysis of mutations and translocations across breast cancer subtypes
Banerji, S., Cibulskis, K., Rangel-Escareno, C., Brown, K. K., Carter, S. L., Frederick, A. M., Lawrence, M. S., Sivachenko, A. Y., Sougnez, C., Zou, L., et al. (2012) · Nature · doi:10.1038/nature11154 · Cited by 1,179
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166 · cited 1×
“Rewired signalling pathway activation through other growth factor receptors, as well as a change in the subtype from that of the primary tumour in metastatic lesions 7 , may also arise from gene expression level heterogeneity in individual tumour cells.”
T-cell exhaustion in the tumor microenvironment
Jiang, Y., Li, Y., & Zhu, B. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.162 · Cited by 1,157 · cited 1×
“Interestingly, these T cells also manifested immuno-suppressive phenotypes of exhausted 39,40 or regulatory T cells 41 .”
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
Wang, Y., Waters, J., Leung, M. L., Unruh, A., Roh, W., Shi, X., Chen, K., Scheet, P., Vattathil, S., Liang, H., et al. (2014) · Nature · doi:10.1038/nature13600 · Cited by 1,029 · cited 1×
“Genetic heterogeneity in breast cancer has been demonstrated at a single-cell resolution with high levels of genome coverage 5 .”
Boeva, V., Popova, T., Bleakley, K., Chiche, P., Cappo, J., Schleiermacher, G., Janoueix-Lerosey, I., Delattre, O., & Barillot, E. (2012) · Bioinformatics · doi:10.1093/bioinformatics/btr670 · Cited by 1,007
RNA-SeQC: RNA-seq metrics for quality control and process optimization
DeLuca, D. S., Levin, J. Z., Sivachenko, A., Fennell, T., Nazaire, M.-D., Williams, C., Reich, M., Winckler, W., & Getz, G. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts196 · Cited by 899
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
Lawson, D. A., Bhakta, N. R., Kessenbrock, K., Prummel, K. D., Yu, Y., Takai, K., Zhou, A., Eyob, H., Balakrishnan, S., Wang, C.-Y., et al. (2015) · Nature · doi:10.1038/nature15260 · Cited by 893 · cited 1×
“Carcinoma cells variably expressed aggressive cancer signatures such as epithelial–mesenchymal transition (EMT), stemness, angiogenesis, proliferation 29,30 and recurrence 3,31 (Supplementary Fig.”
Wirapati, P., Sotiriou, C., Kunkel, S., Farmer, P., Pradervand, S., Haibe-Kains, B., Desmedt, C., Ignatiadis, M., Sengstag, T., Schütz, F., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2124 · Cited by 891
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., & Sotiriou, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4756 · Cited by 828 · cited 1×
“The putative breast cancer cells were further classified into molecular subgroups using joint distribution between the ER and HER2 module scores, scaling the ER and HER2 signalling, respectively 27,28 .”
Quantitative assessment of single-cell RNA-sequencing methods
Wu, A. R., Neff, N. F., Kalisky, T., Dalerba, P., Treutlein, B., Rothenberg, M. E., Mburu, F. M., Mantalas, G. L., Sim, S., Clarke, M. F., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2694 · Cited by 696 · cited 1×
“We isolated single cells using microfluidic chips 23 without prior cell type selection to generate RNA-seq data containing 5.8 ± 1.3 million reads from the amplified cDNAs of each single cell (Supplementary Data 3).”
InfluentialGruvberger-Saal, S. K., Ringnér, M., Chen, Y., Panavally, S., Saal, L. H., Borg, Å., Fernö, M., Peterson, C., & Meltzer, P. S. (2001) · PubMed · Cited by 673
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
Nguyen, L. T., & Ohashi, P. S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3790 · Cited by 627 · cited 1×
“47) have begun.”
Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
Sparano, J. A., & Paik, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1068 · Cited by 617 · cited 1×
“Gene expression-based molecular subtyping has also been broadly applied to breast cancer to aid treatment decisions 3,4 .”
Targeting tumor-associated macrophages as a novel strategy against breast cancer
Luo, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27648 · Cited by 552 · cited 2×
“Tumour-associated macrophages (TAMs) often promote tumour progression and metastasis, whereas CD8 þ cytotoxic T cells and CD4 þ Th1 cells elicit antitumour immunity and suppress tumour growth 13 .”
Lee, J. H., Daugharthy, E. R., Scheiman, J., Kalhor, R., Ferrante, T. C., Terry, R., Turczyk, B. M., Yang, J. L., Lee, H. S., Aach, J., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2014.191 · Cited by 529
Self-citationTriple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J.-S., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 489 · cited 1×
“Although the results of initial subtype studies suggest that the majority of TNBC tumours belong to the basal-like subgroup, TNBC and basal-like breast cancer may not represent identical tumour entities 35 .”
Clinical Application of the 70-Gene Profile: The MINDACT Trial
Cardoso, F., Van't Veer, L., Rutgers, E., Loi, S., Mook, S., & Piccart-Gebhart, M. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3222 · Cited by 464 · cited 1×
“To remove cells with low-quality sequencing values, four filtering criteria were applied: (1) number of total reads; (2) mapping rate; (3) number of detected genes; and (4) portion of intergenic region.”
Transcriptional analysis of the B cell germinal center reaction
Klein, U., Tu, Y., Stolovitzky, G. A., Keller, J. L., Haddad, J., Miljkovic, V., Cattoretti, G., Califano, A., & Dalla-Favera, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437996100 · Cited by 409 · cited 1×
“In the detailed analysis, two subclasses of B lymphocytes were identified, one with an expression signature of centroblasts/centrocytes 38 and the other with that of naive B lymphocytes (Supplementary Fig.”
The first five years of single-cell cancer genomics and beyond
Navin, N. E. (2015) · Genome Research · doi:10.1101/gr.191098.115 · Cited by 371
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 369
A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes
Haibe-Kains, B., Desmedt, C., Loi, S., Culhane, A. C., Bontempi, G., Quackenbush, J., & Sotiriou, C. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr545 · Cited by 313 · cited 1×
“The whole exome sequencing (WES) coverage was 100 (cid:2) for tumours and 50 (cid:2) for paired blood samples.”
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer
Chen, X., Li, J., Gray, W. H., Lehmann, B. D., Bauer, J. A., Shyr, Y., & Pietenpol, J. A. (2012) · Cancer Informatics · doi:10.4137/cin.s9983 · Cited by 292 · cited 1×
“Triple negative breast cancer cells were classified into six subtypes using TNBCtype (http://cbc.mc.vanderbilt.edu/tnbc/ index.php) 59 (Fig.”
Kim, K.-T., Lee, H. W., Lee, H.-O., Kim, S. C., Seo, Y. J., Chung, W., Eum, H. H., Nam, D.-H., Kim, J., Joo, K. M., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0692-3 · Cited by 268
Self-citationc-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry
Prall, O. W. J., Rogan, E. M., Musgrove, E. A., Watts, C. K. W., & Sutherland, R. L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.8.4499 · Cited by 267 · cited 1×
“Most carcinoma cells in all luminal tumours (BC01, BC02 and BC03) expressed high levels of ER and the canonical ER pathway genes 20,33,34 (Fig.”
The prognostic significance of B lymphocytes in invasive carcinoma of the breast
Mahmoud, S. M. A., Lee, A. H. S., Paish, E. C., Macmillan, R. D., Ellis, I. O., & Green, A. R. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1620-1 · Cited by 261
Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells
Singh, J. K., Simões, B. M., Howell, S. J., Farnie, G., & Clarke, R. B. (2013) · Breast Cancer Research · doi:10.1186/bcr3436 · Cited by 249 · cited 1×
“46).”
Inhibitory Receptors Beyond T Cell Exhaustion
Fuertes Marraco, S. A., Neubert, N. J., Verdeil, G., & Speiser, D. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00310 · Cited by 244
B cell regulation of the anti-tumor response and role in carcinogenesis
Schwartz, M., Zhang, Y., & Rosenblatt, J. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0145-x · Cited by 244 · cited 5×
“Previous reports suggest that TAMs may show an immunosuppressive M2 signature, which promotes tumorigenesis by suppressing immune surveillance and inducing angiogenesis, rather than the activating M1-type signature 45 .”
InfluentialGenetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Hu, X., Stern, H. M., Ge, L., O'Brien, C., Haydu, L., Honchell, C. D., Haverty, P. M., Peters, B. A., Wu, T. D., Amler, L. C., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0107 · Cited by 217
Ng, C. K. Y., Martelotto, L. G., Gauthier, A., Wen, H., Piscuoglio, S., Lim, R. S., Cowell, C. F., Wilkerson, P. M., Wai, P. T., Rodrigues, D. N., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0657-6 · Cited by 146
Signatures of human regulatory T cells: an encounter with old friends and new players
Pfoertner, S., Jeron, A., Probst‐Kepper, M., Guzmán, C. A., Hansen, W., Westendorf, A. M., Toepfer, T., Schrader, A. J., Franzke, A., Buer, J., et al. (2006) · Genome biology · doi:10.1186/gb-2006-7-7-r54 · Cited by 106
Fumagalli, D., Blanchet-Cohen, A., Brown, D. N., Desmedt, C., Gacquer, D., Michiels, S., Rothé, F., Majjaj, S., Salgado, R., Larsimont, D., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-1008 · Cited by 64 · cited 1×
“Carcinoma cells variably expressed aggressive cancer signatures such as epithelial–mesenchymal transition (EMT), stemness, angiogenesis, proliferation 29,30 and recurrence 3,31 (Supplementary Fig.”
Delineating cancer evolution with single-cell sequencing
Navin, N. E. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac8319 · Cited by 43 · cited 1×
“Characterization of heterogeneous tumour signatures will lead to effective molecular targeted therapies, whereas characterization of tumour-infiltrating immune cells may reveal a better strategy for overcoming immune suppression and revitalizing the naturally occurring immune surveillance 18 .”
Cited by
Scenic: single-cell regulatory network inference and clustering.
Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520
“57, 73 , Figure 3 and 6a ).”
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
“TAMs harbor highly plastic phenotypes and can be induced to polarize toward classically activated (M1) or alternatively activated (M2) phenotypes to exert immunostimulatory or immunosuppressive functions in tumor immunity.207,208 M1 macrophages exhibit a proinflammatory phenotype with tumor-killing capability, while M…”
BackgroundInfluentialMachine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.034 · Cited by 2,180
“BRCA Single Cell RNA expression (Chung et al., 2017) GEO: GSE75688”
BackgroundMethodSelf-citationLandscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.003 · Cited by 1,624
Lei, X., Lei, Y., Li, J.-K., Du, W.-X., Li, R.-G., Yang, J., Li, J., Li, F., & Tan, H.-B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.009 · Cited by 1,470
Metadata
- Authors
- Chung, W., Eum, H. H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H. S., Kim, S., Lee, J. E., Park, Y. H., Kan, Z., Han, W., & Park, W.-Y.
- Affiliations
- Samsung Medical Center (KR)
- Seoul National University (KR)
- Pfizer (United States) (US)
- Corresponding author
- Han, Wonshik
- Park, Woong-Yang
- ORCID
- Venue
- Nature Communications
- Published
- 2017-05-05
- Volume
- 8
- Issue
- 1
- Pages
- 15081-15081
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5424158
- OpenAlex
- W2610509384
- Cited by
- 992
- References
- 62
- Citations by year
- 2026: 57 · 2025: 85 · 2024: 116 · 2023: 117 · 2022: 148 · 2021: 191 · 2020: 106 · 2019: 93 · 2018: 63 · 2017: 11
- FWCI
- 30.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation
- National Research Foundation of Korea (2015R1A2A2A01008264, 2016R1A5A1011974)
- Samsung
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- breast cancer, intratumoral heterogeneity, tumor immune microenvironment, tumor stroma, T cells, B cells, macrophages, regulatory T cells, T cell exhaustion, M2 macrophages, tumor subtypes, tumor transcriptome, copy number variation
- MeSH terms
- Exome Sequencing, B-Lymphocytes, Breast Neoplasms, Female, Humans, Lymph Nodes, Macrophages, Receptors, Estrogen, Receptors, Progesterone, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Sequence Analysis, RNA, Carcinoma, Ductal, Breast, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Gene Expression Profiling, DNA Copy Number Variations, Single-Cell Analysis, Tumor Microenvironment, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.